Profiel
Dr. Michael Beckert, MD MBA, was Chief Medical Officer at Ascendis Pharma A/S.
Dr. Beckert was previously employed as Chief Medical Officer & Executive Vice President by LifeCycle Pharma A, Medical Director by SkyePharma Plc, and Chief Medical Officer by Scil Biomedical GmbH.
He received his MBA from Donau-Universität Krems and a doctorate degree from Freie Universität Berlin.
Eerdere bekende functies van Michael Beckert
| Bedrijven | Functie | Einde |
|---|---|---|
| ASCENDIS PHARMA A/S | Hoofd Techniek/Wetenschap/O&O | 26-02-2016 |
| VELOXIS PHARMACEUTICALS A/S | Hoofd Techniek/Wetenschap/O&O | 31-12-2008 |
| SKYEPHARMA PLC | Corporate Officer/Principal | 01-01-2004 |
Scil Biomedical GmbH
 Scil Biomedical GmbH Pharmaceuticals: MajorHealth Technology Scil Biomedical GmbH provides pharmaceutical preparations. The private company is based in Munich, Germany. | Hoofd Techniek/Wetenschap/O&O | 01-01-2002 |
Opleiding van Michael Beckert
| Freie Universität Berlin | Doctorate Degree |
| Donau-Universität Krems | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
SkyePharma Plc
 SkyePharma Plc Pharmaceuticals: OtherHealth Technology SkyePharma Plc engaged in the provision of pharmaceutical business. It involved in development and supply of pharmaceutical products. The company was founded by Ian Roderick Gowrie-Smith on August 18, 1910 and was headquartered in London, the United Kingdom. | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Scil Biomedical GmbH
Scil Biomedical GmbH Pharmaceuticals: MajorHealth Technology Scil Biomedical GmbH provides pharmaceutical preparations. The private company is based in Munich, Germany. | Health Technology |
